Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplant Glomerulopathy Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Transplant Glomerulopathy
Interventions
Acthar gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced May 22, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Complement Mediated Diseases
Interventions
AMY-101
Drug
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced May 22, 2026, 5:46 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Proteinuria, Transplant Glomerulopathy
Interventions
Acthar
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced May 22, 2026, 5:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced May 22, 2026, 5:46 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced May 22, 2026, 5:46 AM EDT